Philip founded Geneva Network in 2015. His main research interests are the intersection of intellectual property, trade, and health policy. Formerly he was an official at the World Intellectual Property Organization (WIPO) in Geneva, where he worked in its Global Challenges Division on a range of IP and health issues. Prior to his time with WIPO, Philip worked as director of policy for International Policy Network, a UK-based think tank, as well as holding research positions with the Adam Smith Institute and Reform, both in London. He has also worked as a political risk consultant and a management consultant. He is a regular columnist in a wide range of international newspapers and has published a number of academic studies. He holds degrees from the London School of Economics and Durham University (UK). He is also a Senior Fellow at the Institute for Democracy and Economic Affairs, Malaysia.
El país podría construir una bioeconomía si trabajara en reducir las barreras regulatorias. Por ejemplo, en promedio toma 225 días para que el gobierno apruebe una prueba clínica. En Singapur es menos de un mes.
Intellectual property reforms ushered in by TRIPS have stimulated a nascent boom in pharmaceutical innovation in middle-income countries.
América Latina enfrenta otro año de contracción económica de acuerdo a los últimos pronósticos de la OCDE y la Cepal. Los economistas coinciden en que la región está condenada a un desempeño mediocre en tanto continúe dependiendo de las materias primas.
The UN High Level Report on Access to medicines threatens the nascent boom in biopharmaceutical…
China and South Korea’s attempt to protect domestic industries is rooted in the faulty economic logic of the past. Domestic high-tech sectors are unlikely to develop if they are shielded from international trade and competition behind tariff walls.
For Indonesia to join the ranks of high-income countries in the longer term it needs to start building a knowledge economy. Indonesia’s new patent law is a step in the wrong direction.
By turning back the clock on intellectual property, the U.N. would cut off developing countries from innovation.
Colombia’s compulsory license for a cancer medicine puts at risk its hard earned reputation as a safe country for foreign investment.
Canadian courts have turned patent utility requirements into a test of an inventor’s ability to predict the future.